TAC1 and migraine disorder: Other targets for migraine therapy focusing on the supposed pathophysiological role of neuroinflammation in inducing migraine attacks—such as substance P, neurokinin 1 receptors [99] and orexin receptors [100]—have consistently failed in clinical trials in recent years.